Daiichi Sankyo in $135-Million ADC Manufacturing ExpansionBy
Daiichi Sankyo is making an initial Japanese yen 15 billion ($135 million) investment into three of its manufacturing plants in Japan to expand manufacturing capabilities in support of its antibody drug conjugate (ADC) pipeline. The expansion will supply fully synthesized ADCs for future investigational and commercial use.
Daiichi Sankyo’s proprietary ADC technology is designed to deliver cancer cell destruction with less systemic exposure to the cytotoxic payload. according to the company. The company has six ADCs in its pipeline, including two in Phase I clinical development and four in pre-clinical development.
Source: Daiichi Sankyo